The National Cancer Institute has shown support for the new Austrian HPV vaccine. This support means a milestone for the developers of this vaccine, which may lay the foundation for the necessary clinical trials needed to license this as a viable treatment option. The National Cancer Institute is showing support for the clinical development of an improved HPV vaccine. It is important to note here that the said vaccine had already proved its efficacy in the preclinical study that was carried out in 2013.
The vaccine has won the support of the National Cancer Institute after it emerged as a winner in the selection process of the institute’s prevent cancer program, which means a minimum amount of $3.5 million will be awarded for further research and development. This new Austrian HPV vaccine is now at a stage where the following year and a half will witness its production in the U.S. under the current medicine manufacturing practice.
The second stage will witness the vaccine being prepared for licensing as Investigational New Drugs, known as IND, by the Food and Drug Administration, which is crucial for initiating the already planned, early phase human clinical trials. The term GMP, or the good manufacturing process, is used to designate the guidelines for ensuring environmental and production sequences quality, especially the guidelines related to the manufacturing of active ingredients and medicines. This was first introduced by the FDA in 1962 through the initiation of current Good Manufacturing Practice.
In the preclinical tests and laboratory studies, the new Austrian HPV vaccine has already performed well and proved to be effective against a range of low- and high-risk HPV types as compared to the vaccines that are already available on the market. The feature that lends an edge to this vaccine is its demonstrated ability to protect against HPV, which is known to cause several types of skin warts and may lead to grave health concerns for individuals, especially those who are immune-suppressed.
Five research clusters, namely immunology, medical neurosciences, cardiovascular medicine, oncology research, and medical imaging, have been set up at the MedUni Vienna, which is aimed at increasing focus in the fields of clinical and fundamental research.
The new Austrian HPV vaccine, which shows promising results thus far, is therefore a great breakthrough in fighting HPV and offers a ray of hope for all those who are vulnerable to HPV.